Sep 17, 2026
Chinese internet company ByteDance has completed a $290 million fundraising round for its artificial intelligence drug discovery unit after spinning it off as a separate entity called Anew Labs. The funding values the newly independent company at $1.5 billion.
Insilico Medicine announced that rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reduce biological age markers in a 42-patient trial. Six independently built aging clocks all showed patients on the drug appeared biologically younger, according to a study conducted with researchers from Harvard Medical School, Stanford University, and The Broad Institute.
Rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reverse biological signs of aging in a study, according to its developer, suggesting broader potential applications beyond its original target condition.
Michael Polansky's biotech startup Outer Biosciences has emerged from stealth after four years, revealing technology that keeps surgically discarded human skin tissue alive for up to a month outside the body. The company trains AI models on how the living tissue reacts to compounds to discover new skincare treatments.
Outer Biosciences, founded by Michael Polansky (Lady Gaga's partner and former Sean Parker deputy), has emerged from four years in stealth mode. The biotech startup keeps surgically discarded human skin tissue alive for up to a month outside the body and uses AI models to predict useful skincare compounds.
An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.
ALZpath announced a global licensing deal with Abbott Laboratories to advance blood-based testing for Alzheimer's disease, joining the race to develop easier-to-use diagnostic options for the neurodegenerative condition.
The first participant has been treated in a groundbreaking clinical trial testing cellular reprogramming technology designed to rejuvenate aging cells. This marks the first time such reverse-aging therapy has been administered to a human.
Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, announced it has raised additional funding at a $1.8 billion valuation, marking significant investor confidence in the anti-aging research space.
Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.
BioAge Labs announced its investigational pill for cardiovascular risk prevention significantly reduced inflammation markers in an early-stage clinical study, representing potential progress in heart disease prevention.
Abu Dhabi Stem Cells Center has achieved a breakthrough in regenerative medicine by developing a technique that allows scientists to generate brain stem cells using a patient's own cells, advancing personalized medicine approaches.
Scientists at the Buck Institute for Research on Aging demonstrated that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones in preclinical studies.